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Cutaneous T cell lymphoma (CTCL) is a clonal epider-
motropic malignancy of memory T cells (mTCs) pri-
marily involving the skin. Mycosis fungoides (MF),
the subtype of CTCL with the highest prevalence rate,
typically presents as cutaneous patches or plaques,
which may progress to tumor stages, while Sézary
syndrome (SS), the erythrodermic variant of CTCL,
may develop either de novo or following certain stages
of classic MF [1]. Despite its diverse clinical features,
one common feature of CTCL is its migration to skin,
although to various extents in different subtypes.
However, our current knowledge of the mechanisms
regulating migration of CTCL is still limited.
It has been suggested that, for certain typical
inflammatory skin diseases (e.g. atopic dermatitis),
in order to migrate to skin, different lines of T cells
adopt a complicated multiple-step adhesion cascade
(tethering, rolling, and adhesion), in which chemo-
kines and their receptors play a pivotal role, to leave
the blood flow and transmigrate through endothelial
cells into skin [2,3]. Importantly, certain chemokines
and their receptors have been demonstrated to be
highly expressed in inflammatory skin diseases, indi-
cating possible important roles for them during the
process. For example, the chemokine receptor CCR4
was found to be highly expressed by certain types of
T cells in the peripheral blood of patients with atopic
dermatitis, while CCL17 (also known as thymus and
activation-regulated chemokine, or TARC), one of the
ligands for CCR4, was found to be upregulated in
lesional keratinocytes [4].
However, it remains elusive whether malignant
clonal T cells of CTCL may also adopt multistep
Received: Sep 9, 2008 Accepted: Nov 18, 2008
Address correspondence and reprint requests to:
Dr Meng-Tse Wu, Department of Dermatology,
China Medical University, 2 Yuh Der Road,
Taichung 404, Taiwan.
E-mail: d5313@mail.cmuh.org.tw
DIFFERENTIAL CCR4 EXPRESSION AND FUNCTION
IN CUTANEOUS T-CELL LYMPHOMA CELL LINES
Chieh-Shan Wu,1 Sin-Ting Wang,2 Chai-Yu Liao,2 and Meng-Tse Wu2
1Department of Dermatology, Faculty of Medicine, College of Medicine, Kaohsiung Medical University,
Kaohsiung, and 2Department of Dermatology, China Medical University, Taichung, Taiwan.
Cutaneous T cell lymphoma (CTCL) is a clonal epidermotropic malignancy of memory T cells
primarily involving the skin. However, the mechanisms governing migration of CTCL cells have
not been fully clarified. It has been shown that certain chemokine receptors are upregulated in
CTCL cells, but it remains unanswered whether these chemokine receptors play a critical role in
the migration dynamics of CTCL. Using cell lines originally derived from patients with different
subtypes of CTCL, we have shown higher CCR4 expression in the line derived from the mycosis
fungoides (MJ), compared with the line derived from Sézary syndrome (Hut78). In specific
responses to CCL22 (a CCR4 ligand) treatments, MJ cells showed significant chemotactic migra-
tion, enhanced activation and adhesion of certain integrins (CD49d and CD29) in vitro, while the
control cells (Hut78, CD4+CD45RO+ memory T cells, and Jurkat cells) did not. Furthermore,
compared with Hut78 cells, MJ cells manifested significantly more transendothelial migration in
responses to treatments with either CCL22 or conditioned medium from dendritic cells in vitro.
These results provide further dynamic evidence, in line with the multistep cascade paradigm for
leukocyte transendothelial migration, to support a critical role for CCR4 in CTCL migration.
Key Words: CCR4, chemokine, cutaneous T-cell lymphoma
(Kaohsiung J Med Sci 2008;24:577–90)
Kaohsiung J Med Sci November 2008 • Vol 24 • No 11578
C.S. Wu, S.T. Wang, C.Y. Liao, and M.T. Wu
adhesion mechanisms to migrate. Among few reports
that have addressed this issue, Heald et al have shown
that T cells expressing cutaneous lymphocyte antigen
(CLA), an adhesion molecule well known to mediate
skin migration of T cells, correlate with disease extent
in SS and decline with clinical remission [5]. Shiohara
et al proposed that LFA-1 (CD11a/CD18) integrin ex-
pression by T cells may play a role in the epidermotro-
pism of malignant T cells [6]. In contrast, Hwang and
Fitzhugh reported a case of SS with downregulated
expression of LFA-1 (CD11a/CD18), but upregulation
of L-selectin (CD62L) [7]. More recently, several reports
have focused on the expression of chemokines and
chemokine receptors by CTCL. Kallinich et al demon-
strated differential expression patterns of chemokine
receptors in T cells at different stages (patch/plaque
versus tumor stages) [8], finding that the chemokine
receptors CCR4, CXCR3 and CXCR4 are highly
expressed by MF T cells at early stages. Meanwhile,
Kakinuma et al showed that the serum level of che-
mokine CCL17 (TARC), one of the ligands for CCR4,
correlates with disease severity of MF, indicating that
CCR4 and its chemokine ligands may play a role in
the pathogenesis of MF [9].
We hence postulated that CCR4, beyond expression
by CTCL cells, may play a critical role in the migration
of CTCL cells through a multistep adhesion cascade
causing transendothelial movement of leukocytes. By
using different CTCL cell lines (MJ and Hut78; derived
from MF and SS respectively), we found differential
expression of CCR4 (much more in MF-derived MJ
cells than in SS-derived Hut78 cells). In serial func-
tional assays (in line with the current adhesion cas-
cade paradigm) to test whether CCR4 may play an
important role in CTCL migration, MJ cells showed
greater responses to CCR4 ligands (mainly CCL22,
also known as macrophage-derived chemokine, or
MDC) than other cells (Hut78, CD4+CD45RO+ mTCs,
and Jurkat cells as controls). Our results thus further
support the postulation that CCR4 signaling may be
functionally important in CTCL migration.
MATERIALS AND METHODS
Cell lines, antibodies, and reagents
Originally from the American Type Culture Collec-
tion (Manassas, VA, USA), human HH, Hut78, MJ,
and Jurkat (clone E6-1) cell lines, derived from
patients with non-MF CTCL tumors [10], SS [11], MF
[12], and acute T-cell leukemia [13] respectively, were
purchased from a local provider, National Health
Research Institute Cell Bank (Hsin Chu, Taiwan). HH
and Jurkat cells were cultured in RPMI 1640 (GIBCO,
Invitrogen, Rockville, MD, USA) with 10% fetal
bovine serum (GIBCO, Invitrogen). Hut78 and MJ
cells were cultured in Iscove’s modified Dulbecco’s
medium (GIBCO, Invitrogen) with 20% FBS. Human
dendritic cells (DCs) were purchased from Lonza
(Basel, Switzerland), and HaCaT cells (an immor-
talized keratinocyte cell line) were provided by Dr
H.S. Yu of Kaohsiung Medical University. All cell lines
were maintained at 37°C in a humid atmosphere of
5% CO2. Recombinant human chemokine CCL22, re-
combinant human TNF-α, and recombinant human
VCAM-1/Fc chimera were purchased from R&D sys-
tems (Minneapolis, MN, USA). The following mono-
clonal antibodies (mAbs) were used in this study:
fluorescein isothiocyanate (FITC)-conjugated anti-
human CD4, phycoerythrin (PE)-conjugated anti-
human CD45RO, PE-conjugated anti-human CD29,
PE-conjugated anti-human CD49d, FITC-conjugated
mouse IgG2b, and PE-conjugated mouse anti-IgG1
were from Biolegend (San Diego, CA, USA); FITC-
conjugated anti-human CCR4 and anti-human CCL22
neutralizing antibody (Ab) were from R&D systems;
FITC-conjugated AffiniPure F(ab’)2 fragment of goat
anti-human IgG (Fc specific) was from Jackson
ImmunoResearch Laboratories (West Grove, PA, USA);
and function-blocking anti-CD49d (α4 integrin) mAb
(clone: HP2/1) was from Serotec (Raleigh, NC, USA).
The appropriate isotype controls used were unlabeled
mouse IgG1 and unlabeled mouse IgG2b, purchased
from R&D systems, and FITC-conjugated mouse IgG1
and PE-conjugated mouse IgG2a κ, purchased from BD
Biosciences (San Jose, CA, USA). Other reagents used
were calcein-acetoxymethyl ester (or known as cal-
cein AM, Molecular Probe, Invitrogen), Ficoll-Paque
(Amersham Biosciences, GE Healthcare, Piscataway,
NJ, USA), Hank’s balanced salt solution (HBSS; Sigma-
Aldrich, St. Louis, MO, USA), HEPES (Sigma-Aldrich),
manganese chloride (Sigma-Aldrich), and pertussus
toxin (PTX; Calbiochem, San Diego, CA, USA).
Detection of CCR4 expression
CCR4 expression was detected by real-time quantita-
tive PCR (qPCR) and flow cytometry. For qPCR, total
RNA was isolation from cell pellets using RNeasy kits
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(Qiagen, Valencia, CA, USA) according to the manu-
facturer’s instructions. First-strand cDNA was gener-
ated from total RNA using a commercial kit for reverse
transcription (Superscript First-Strand Synthesis Sys-
tem; Invitrogen). Real-time qPCR was performed
using an ABI PRISM® 7900 DNA Sequence Detection
System and SYBR® Green (Applied Biosystems, Foster
City, CA, USA) to quantify the PCR products as
described [14]. Human glyceraldehyde 3-phosphate
dehydrogenase (G3PDH) was used as an internal con-
trol. Specific primer pairs for CCR4 (5-CAATACT-
GTGGGCTCCTCCAA-3 and 5-ATCCATGGTGGA-
CTGCGTGTA-3) and G3PDH (5-TGGGCTACACT-
GAGCACCAG-3 and 5-CAGCGTCAAAGGTGG-
AGGAG-3) were designed using Primer Express
software (Applied Biosystems). Cycle threshold num-
bers (Ct) were derived from the exponential phase of
PCR amplification. Fold differences in expression of
gene x in cell populations y and z were derived by 2k,
where k= (Ctx−CtG3PDH) population y− (Ctx−CtG3PDH)
population z [14]. For flow cytometric analysis, cells
were stained at 4°C with FITC-conjugated anti-human
CCR4. After washing, cells were analyzed using a
FACScan flow cytometer (BD Biosciences).
Chemotaxis assay
The chemotaxis response to chemokines was assessed
using the ChemoTx® disposable chemotaxis assay
system (Neuro Probe; Gaithersburg, MD, USA) as
previously reported [15]. Cells were labeled with cal-
cein AM and suspended in medium (2 × 106 cells/mL),
and a 25-μL cell suspension was added to the top side
of the filter. Cells were then exposed to basal medium
only or chemokine (CCL22 or CCL17) at 10 or 100 ng/
mL, in the presence of other agents (neutralizing anti-
CCL22 Ab at 16 μg/mL, isotype for anti-CCL22 Ab 
at 16 μg/mL, or PTX at 100 ng/mL) or not. Plates
were then incubated for 3 hours at 37°C [16]. After
incubation, cells migrating through the filter were
counted in three randomly selected microscopic fields
(40×) per well. The normalized migration index for
each cell type was calculated using the control group
(medium only) as the base level.
Integrin activation assay
To determine whether CCR4 signaling enhances inte-
grin activation (conformation change to increase avid-
ity for its ligand), cells were suspended in binding
medium (HBSS containing BSA at 2 mg/mL, HEPES
at 10 mM, Ca2+ at 1 mM, and Mg2+ at 1 mM; pH at
7.4), with or without CCL22, in the presence of other
agents to test CCL22 dependence (anti-CCL22 Ab, iso-
type for anti-CCL22, or PTX) or not, and incubated for
10 minutes at 37°C. Cells were then washed and sus-
pended in binding medium in the presence of several
mAbs against integrins, including PE-conjugated anti-
human CD29 and anti-human CD49d (targeting α4β1
integrin, from Biolegend), for 30 minutes at 4°C [17].
Cells were washed and then analyzed immediately
with the flow cytometer.
Integrin adhesion assay
In order to further determine whether CCR4 signaling
in MJ cells may actually enhance binding of integrin(s)
to their ligands on endothelial cells, a soluble binding
assay and static cell adhesion assay were performed.
For the soluble binding assay, 2 × 105 cells were sus-
pended in 50 μL of binding medium and exposed to
different conditions, including medium alone, CCL22
or CCL17 (100 ng/mL) only, or CCL22 with other
agents, including anti-human CCL22 neutralizing 
Ab (16 μg/mL for 10 minutes at 37°C), mouse IgG2B
isotype control for anti-CCL22 (16 μg/mL for 10 min-
utes at 37°C), or PTX (100 ng/mL for 2 hours at 37°C)
[18]. As described previously [19,20], soluble human
VCAM-1/Fc chimera (ligand for α4β1 integrin, at
20 μg/mL) was added and incubated for 75 seconds
at 37°C. Cells were then washed with ice-cold binding
medium to stop binding. Binding of soluble VCAM-
1/Fc was detected with FITC-conjugated AffiniPure
F(ab’)2 fragments of goat anti-human IgG (specific for
Fc) by flow cytometry. In some experiments (Figure
4C), pretreatment with function-blocking anti-CD49d
(clone: HP2/1) mAb (10μg/mL for 10 minutes at 37°C)
was also performed to determine whether binding of
integrin ligand (VCAM-1) is also integrin dependent
(except chemokine dependent). For the static cell adhe-
sion assay, as described previously [20,21] with some
modifications, 96-well plates were coated with recom-
binant human VCAM-1/Fc (1 μg/mL in binding
medium, 100 μL) and incubated overnight at 4°C.
Wells were then washed with bicarbonate buffer 
and incubated either with the presence of CCL22
(100 ng/mL), Mn2+ (1 mM MnCl2 in binding medium),
or binding medium only, for 30 minutes at room tem-
perature. Cells (1 × 105 cells per 50 μL of binding me-
dium) were then added to the wells and incubated at
37°C for 30 minutes. Wells were washed four times
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with binding medium to remove non-adherent cells.
To quantify the adherent cells, cell proliferation assay
kit from Biovision (Mountain View, CA, USA) was
used. A total of 100 μL of RPMI 1640 medium and
10 μL of WST-1 solution was added to each well and
incubated at 37°C for 2 hours. The plates were then
analyzed using an ELISA plate reader to read
absorbance at 450 nm.
Transendothelial migration assay with
chemokine or conditioned medium treatment
Endothelial cells (ECs) derived from human skin
(HMEC-1) [22] were grown to confluence on the inserts
of Transwell plates (5-μm pore size; Corning Costar,
High Wycombe, United Kingdom). The confluent
monolayers were incubated for 12 hours with TNF-α
(10 ng/mL) to induce cell surface VCAM-1 expression
[20]. Cells were labeled with calcein AM and sus-
pended at 1 × 106/mL in medium, and 100 μL of this
cell suspension was added to the inserts. Cells were
then exposed to different conditions in the lower cham-
bers of Transwell plates as indicated (Figure 5A),
including medium alone, CCL22 (100 ng/mL) only,
and CCL22 plus other agents including anti-human
CCL22 neutralizing Ab (16 μg/mL), mouse IgG2B iso-
type control (16 μg/mL), or PTX (100 ng/mL) [18].
Plates were incubated for 6 hours at 37°C [23]. After
incubation, the inserts were removed, and the cells
were counted in three randomly selected microscopic
fields per chamber at a magnification of 40×. The
transendothelial migration index was calculated by
normalization against the medium alone group. In
another series of experiments (Figure 5B), treatments
with or without CCL22 were performed in the pres-
ence or absence of the function-blocking anti-CD49d
(α4 integrin) mAb (10 μg/mL) or its isotype to deter-
mine whether transendothelial migration is also inte-
grin dependent (except chemokine dependent). For
the transendothelial migration assay involving treat-
ment with conditioned medium (CM) from cells
(DCs and HaCaT cells) (Figure 5D), MJ cells were
exposed to basal medium or CM from DCs or HaCaT
cells, plus other agents, including anti-CCL22 neu-
tralizing mAb (or its isotypes), PTX, or anti-CD49d
neutralized mAb (or its isotype).
Cell viability assay for MJ cells
Cells were seeded in 96-well plates (104 cells per well)
in 90 μL of culture medium containing FBS at only
0.5%. After incubation for 3 hours, cells were treated
with 10 μL of recombinant human CCL22, CCL17, or
CXCL12 (also known as SDF-1) at 50 and 100 ng/mL
concentrations in triplicate. As controls, cells were
also treated with PBS only or culture medium con-
taining 20% FBS. After incubation for 24 hours, a cell
proliferation assay kit from Biovision (Mountain View,
CA, USA) was used to quantify the cell viability.
Immunoblotting for CCR4 signaling in 
MJ cells
MJ cells (1 × 106/mL) were cultured in 24-well plates
for 4 hours at 37°C in serum-free medium and then
treated with CCL22 (100ng/mL). Cells were harvested
at various time points (0, 5, 10, 15, and 20 minutes) for
total protein extraction. The Coomassie Protein Assay
Kit (PIERCE, Rockford, IL, USA) was used to standard-
ize the protein concentrations of the supernatants.
Cell lysates containing 30 μg of protein were separated
by 8% SDS-PAGE and transferred to PVDF membranes.
Membranes were blotted with various mAbs (anti-
human/mouse/rat pan-Akt, affinity-purified rabbit
anti-phospho-Akt (S473), anti-human/mouse/rat pan-
ERK1/ERK2, and anti-phospho-ERK1/ERK2(T202/
Y204) (R&D systems) at 4°C overnight. Secondary
Abs were added, and the bands were developed by
enhanced chemiluminescence (ECL).
Statistical analysis
The data are presented as mean ± standard deviation.
Data were analyzed using Student’s t tests (two-sided,
parametric). Statistical significance was determined
at p < 0.05. Unless indicated otherwise, experiments
were performed at least three times. Representative
data are presented.
RESULTS
Expression of the chemokine receptor CCR4
by different CTCL cell lines
Using qPCR and flow cytometry, we measured and
compared relative expression levels of the chemokine
receptor CCR4 in two CTCL lines (MJ and Hut78),
Jurkat cells (human leukemia T cell line), and CD4+
CD45RO+ mTCs. By qPCR, higher expression of CCR4
was detected in MJ cells (∼8.7-fold versus Hut78 cells
by qPCR, Figure 1A), while Hut78 cells and other con-
trols (Jurkat cells and CD4+CD45RO+ mTCs) showed
relatively low expression of CCR4 (Figure 1A). A
flow cytometry assay (Figure 1B–E) further demon-
strated relatively high expression of CCR4 by MJ
cells (∼87%) compared with Hut78 cells (∼39%) and
controls (Jurkat cells, ∼43%; mTCs, ∼42%). Since the
MJ cells originated from a patient with MF (the most
typical CTCL subtype composed of predominantly
skin-homing malignant T cells), whereas Hut78 cells
were derived from a patient with SS (with many
malignant T cells remaining in circulation instead of
homing to skin), the differential expression of CCR4
by MJ and Hut78 cells appears to further substantiate
CCR4’s important role in CTCL skin homing.
MJ cells are more responsive to CCL22
(ligand for CCR4) in a chemotaxis assay
To further determine whether CCR4 signaling plays
a critical role in the migration dynamics of MJ cells,
we performed a chemokine functional assay to com-
pare MJ cells with Hut78 cells and other control cells.
As shown in Figure 2A, MJ cells demonstrated greater
chemotaxis toward CCL22 (one of the two ligands for
CCR4 tested) than Hut78 cells (p < 0.01) and control
cells (Jurkat and CD4+CD45RO+ mTCs). The chemo-
taxis response of MJ cells to CCL22 is specific, since it
could be negated by a neutralizing Ab (Anti-CCL22)
and PTX (Figure 2A). Moreover, as shown in Figure 2B,
CCL17 (another ligand for CCR4) may also induce
chemotaxis of MJ cells in a dose-dependent manner,
but to a lesser degree than CCL22, especially at a
higher concentration (100 ng/mL; p < 0.05).
CCL22 treatment may enhance the
activation of VLA-4 a4b1 integrin
(CD49d/CD29) on MJ cells
To address whether CCR4 signaling in MJ cells may
induce a subsequent multiple-step adhesion cascade,
which may lead to eventual transendothelial migra-
tion to skin, we next investigated if CCL22 treatments
enhance integrin activation (that is, conformational
change to increase avidity), integrin adhesion (to its
ligand), and ultimate transendothelial migration. MJ
cells were treated with CCL22 and then subjected 
to a flow cytometric assay to measure the expression
of the active form (with increased avidity) of α4β1
integrin using anti-CD49d and anti-CD29 mAbs able
to detect the active form of integrin as previously
described [17,24]. As shown in Figures 3A and 3B, 
MJ cells demonstrated enhanced expression (activa-
tion) of CD49d (Figure 3A) and CD29 (Figure 3B)
after CCL22 treatment; this reaction is specific to the
CCR4-CCL22 interaction, as anti-CCL22 and PTX,
but not the isotype control, were able to attenuate the
reaction. In contrast, enhanced integrin activation was
not detected in similar assays using Hut78, Jurkat,
and CD4+CD45RO+ mTC cells (data not shown).
Furthermore, CCL17 was also able to enhance the
expression of α4β1 integrin by MJ cells (Figure 3C).
In contrast, neither chemokine (CCL22 and CCL17)
was able to induce enhanced expression of β2 integrin
CCR4 function in CTCL cell lines
Kaohsiung J Med Sci November 2008 • Vol 24 • No 11 581
12
0
0
E
ve
nt
s
MJ
Jurkat mTC
Hut78
87%
43% 42%
39%
100 101 102 103 104 100 101 102 103 104
100 101 102 103 104 100 101 102 103 104
PL1-Height
12
0
0
E
ve
nt
s
PL1-Height
12
0
0
E
ve
nt
s
PL1-Height
12
0
0
E
ve
nt
s
PL1-Height
100
80
60
40
20
0
R
el
at
iv
e 
ex
pr
es
si
on
 o
f C
C
R
4
MJ Hut78 Jurkat mTC
78
9 7
1
A
B C
D E
CCR4
Figure 1. Relatively higher expression of CCR4 by CTCL MJ
cells. (A) Relative expression levels of CCR4 (shown atop the
black bar) in two CTCL lines (MJ and Hut78), Jurkat cells, and
CD4+CD45RO+ mTCs were measured by qPCR. (B–E) Cells were
stained with anti-CCR4 mAb (FITC-conjugated) and measured
by flow cytometry.
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LFA-1 (αLβ2, CD11a/CD18) by flow cytometry (data
not shown).
CCR4 signaling may enhance a4b1 integrin
adhesion to its ligand (VCAM-1) on MJ cells
To further determine whether an interaction between
CCR4 and CCL22 enhances in vitro adhesion of VCAM-
1 (ligand for α4β1 integrin; usually expressed on ECs
by stimulation) to MJ cells via α4β1 integrin (CD49d/
CD29), MJ cells were subjected to a soluble biding
assay by flow cytometry as described previously
[20,25]. As shown in Figure 4A, following CCL22
treatment, CCR4 signaling by CCL22 treatment specif-
ically enhanced adhesion of soluble VCAM-1, as this
reaction could be blocked by either anti-CCL22 or
PTX, but not the isotype control Ab. Moreover, the
CCL22-enhanced VCAM-1 adhesion is indeed inte-
grin dependent, as a neutralizing mAb for CD49d,
but not its isotype control, was able to inhibit the
VCAM-1 adhesion reaction (Figure 4B). In contrast,
soluble VCAM-1 adhesion was not enhanced in
Hut78, Jurkat, and CD4+CD45RO+ mTC cells (data
not shown) after treatment with CCL22. Moreover,
CCL17 treatment was also able to enhance VCAM-1
adhesion to MJ cells, but to a lesser degree (∼15% less
than the level of CCL22-enhanced binding, Figure
4C). To further substantiate the results of the soluble
VCAM-1 binding assay, a static cell adhesion assay
using immobilized VCAM-1 was also performed. 
As shown in Figure 4D, CCL22 treatment may also
enhance the binding of MJ cells to immobilized
VCAM-1 (coated onto the plate), as shown in Figure 4D
(compared with non-chemokine treatment, p < 0.05),
which is comparable to a Mn2+-induced reaction (a
commonly used potent positive control for affinity
regulation) [20].
CCR4-CCL22 interaction may enhance
transendothelial migration of MJ cells
To determine whether CCR4-CCL22 interaction may
ultimately enhance CTCL migration through ECs, an
in vitro transendothelial migration assay to mimic the
real skin milieu was set up by using skin-derived ECs
(HMEC-1) and chemokine treatments (as described in
the Materials and Methods section). As shown in
Figure 5A, CCL22 treatment enhanced the migration
of MJ cells through ECs relative to the migration of
control cells (Hut78, Jurkat, and mTC) (p < 0.05, Figure
5A). This reaction was also CCR4-CCL22 interaction
and integrin dependent, as it could be inhibited by
neutralizing anti-CCL22 Ab, PTX (Figure 5A), and neu-
tralizing Ab for CD49d (Figure 5B), but not by isotype
controls. On the other hand, treatments with CCL17
moderately enhanced the transendothelial migration
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of MJ cells, but to a lesser degree than treatments
with CCL22 (∼1.7-fold above basal level with CCL17
versus ∼4.0-fold with CCL22, p < 0.05; Figure 5B).
DCs may also enhance the transendothelial
migration of MJ cells by CCL22 secretion
It has been shown that DCs are the major source of
CCL22 in the skin milieu [26,27], whereas CCL17 is
mainly derived from keratinocytes (KCs) and ECs. To
further substantiate our in vitro results (using exoge-
nous chemokines CCL22 and CCL17 only), we next
investigated whether human DCs and KCs enhance
the transendothelial migration of CTCL via CCR4-
CCL22 or CCR4-CCL17 interactions. High levels of
expression of CCL22 and CCL17, by DCs and HaCaT
cells (immortalized KCs), respectively, was confirmed
by ELISA assays (using CM from cultured cells) (Figure
5C). Note that CCL22 is predominantly produced by
DCs, but not by HaCaT or HMEC-1 cells, whereas
CCL17 is also found in DC- and HMEC-1-derived CM
(Figure 5C). In the transendothelial migration assay,
as shown in Figure 5D, DC-derived CM was able to
significantly enhance the transendothelial migration
of MJ cells in a similar fashion to CCL22, and this
enhancement could also be blocked by neutralizing
Abs (anti-CCL22 and anti-CD49d) and PTX, indicating
that DC-enhanced transendothelial migration of MJ
cells is also both CCR4-CCL22 interaction and integrin
dependent. In contrast, HaCaT-derived CM could not
significantly enhance the transendothelial migration
of MJ cells beyond the basal level (∼2.1-fold above
basal level with HaCaT-derived CM, versus ∼6.0-fold
with DC-derived CM, p < 0.05; Figure 5D).
Cell survival of MJ cells in response to
CCR4 signaling
As it has been well established that chemokine signal-
ing may have multiple effects, besides cell migration,
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experiments with similar results. X-axis: fluorescent intensity. Y-axis: cellular event number detected by flow cytometer.
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on cancer cells [28], we investigated whether CCR4
signaling also enhances survival of MJ cells. As
shown in Figure 6, under nutrition deprivation (in
0.5% FBS), MJ cells showed enhanced survival
(p < 0.05), compared with non-chemokine controls, 
in the presence of CCL22 or CCL17, which is com-
parable to the effect induced by CXCL12, another
chemokine well established to enhance tumor cell
survival [29].
Immunoblotting for tracing the CCR4
signal transduction route in response 
to CCL22
We further investigated the signaling events in MJ
cells in response to CCL22. As shown in Figure 7, in
response to CCL22 treatment, time-dependent accu-
mulation of phosphorylated serine/threonine kinase,
Akt (or PKB) was observed in MJ cells. In contrast, the
phosphorylation of another signaling effector molecule,
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Figure 4. CCL22 treatment may enhance integrin-dependent adhesion to soluble or immobilized VCAM-1. (A) MJ cells were exposed
to CCL22 treatment or not, in the presence or absence of other agents (neutralizing anti-CCL22 Ab, isotype for anti-CCL22 Ab, and
PTX), to test the dependence on CCL22 treatment, and then incubated with soluble VCAM-1 before flow cytometric analysis of
VCAM-1 adhesion. Dotted line: no CCL22 treatment. Solid line: with the presence of CCL22, plus other agents (anti-CCL22 Ab, isotype
control for anti-CCL22 Ab, or PTX) or not. (B) In another series of experiments, MJ cells were likewise exposed to CCL22 treatment or
not, followed by VCAM-1 incubation and flow cytometric analysis as in (A), but with the presence of function-blocking anti-CD49d
mAb or isotype Ab to test the dependence on a4 integrin (CD49d). Dotted line: no CCL22 treatment. Solid line: with the presence of
CCL22, plus neutralizing anti-CD49d Ab (or isotype for anti-CD49d Ab) or not. (C) In another series of experiments, MJ cells were
exposed to either CCL22 or CCL17 treatment or not, and then subjected to VCAM-1 incubation and flow cytometric analysis. Dotted
line: no chemokine treatment. Solid line: with CCL22 or CCL17 treatment. (A–C) X-axis: fluorescent intensity. Y-axis: cellular event
number detected by flow cytometer. (D) MJ cells were treated with CCL22 or not (null), and put onto either VCAM-1- or BSA-coated
dishes before washing. Adhesion to VCAM-1 (or BSA) is reflected by the number of wash-resistant (adherent) cells, measured by 
a commercial cell proliferation kit, shown as colorimetric reading at 450-nm absorbance. Mn2+ was used in some groups (without
CCL22) as a potent positive control for affinity regulation as previously described [20]. Results represent one of at least two experiments
with similar results (A–D), and are shown as mean ± SD in (D).
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Erk, was not found to be increased above the basal
level in the presence of CCL22.
DISCUSSION
CCR4 has long been considered an important media-
tor for CTCL skin homing; however, most evidence
available to date to support this theory is based on
expressional, rather than functional, studies. In light
of the lack of sufficient functional evidence to support
a critical role of CCR4 in CTCL migration dynamics, we
tried to address this issue and have demonstrated that
CCR4 signaling, induced by CCL22 treatment, specif-
ically enhances chemotaxis, integrin activation, integrin
adhesion, and overall transendothelial migration of
MF-derived MJ cells, while SS-derived Hut78 cells
and other control cells (CD4+CD45RO+ mTCs and
Jurkat cells) did not respond to CCL22 as well. The
present study not only confirms the critical role played
by CCR4 in CTCL trafficking, but also demonstrates
that CCR4-mediated CTCL skin homing may occur in
Figure 5. CCL22 and DC conditioned medium (CM) may enhance the transendothelial migration of MJ cells. (A) Transendothelial
migration of cells (MJ, Hut78, Jurkat, and mTC) was measured following exposure to CCL22 (100 ng/mL), in the presence or absence
of other agents (neutralizing anti-CCL22 Ab, isotype for anti-CCL22 Ab, and PTX). *p < 0.05, MJ versus other types (Hut78, Jurkat,
and mTC) of cells. (B) In another series of experiments, MJ cells were likewise exposed to CCL22 treatment as in (A), but in the pres-
ence of neutralizing anti-CD49d Ab or isotype (for anti-CD49d Ab) to test the dependence on a4 integrin (CD49d). (C) Expression of
CCL22 and CCL17 by DCs, HaCaT cells, and HMEC-1 cells was measured and compared by ELISA, using CM derived from the
respective cell types. (D) In another series of experiments, MJ cells were exposed to DC- or HaCaT-derived CM, with or without the
agents, to test the CCL22 dependence (neutralizing anti-CCL22 Ab, isotype for anti-CCL22 Ab, or PTX), and the agents to test a4
integrin (CD49d) dependence (the neutralizing anti-CD49d Ab or isotype).
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accordance with the current lymphocyte trafficking
paradigm (adhesion and transendothelial migration
cascade) for inflammatory skin diseases.
CCL22 and CCL17 are the only two ligands for
CCR4 and both have been shown to be expressed by
various types of cells in the skin milieu [26,30]. We
were interested in whether there are any differences
between CCL22 and CCL17, with regard to their roles
and relative importance in mediating skin homing of
CCR4-expressing CTCL. Using standard chemotaxis
assays, we first tested the CCR4 function of CTCL
cells, in terms of their responses to treatments with
CCL17 and CCL22. As shown in Figure 2B, CCL22 was
able to induce more chemotaxis of MJ cells than CCL17
(at 100 ng/mL). In integrin activation and adhesion
assays, we also found that CCL22 induces mildly
greater responses in MJ cells than CCL17. Moreover,
CCL22, but not CCL17, could enhance transendothelial
migration of MJ cells beyond the basal level in vitro.
These results are in line with the results of several
previous studies showing that CCL22 is dominant over
CCL17 in several CCR4-mediated reactions [31–33].
D’Ambrosio et al showed that CCL22 is much more
powerful than CCL17 in the induction of integrin-
dependent T cell adhesion to VCAM-1 [31], which is
in accordance with our results (Figure 4). Mariani 
et al demonstrated that CCL22 is a more potent and
rapid inducer of CCR4 internalization and recycling
than CCL17 in Th2 cells [32]. They also noted that,
while incubation of cells with CCL17 inhibited subse-
quent cell migration in response to CCL17, but not 
to CCL22, incubation of cells with CCL22 inhibited
subsequent migration in response to both CCL22 
and CCL17, thus suggesting a hierarchy (CCL22 
over CCL17) of cross-desensitization action between
these two CCR4 ligands. This report appears to pro-
vide a reasonable explanation for our results show-
ing CCL22’s superiority over CCL17 in terms of the
enhancement of basal transendothelial migration of
p-Akt
CCL22 (100 ng/mL)
Total Akt
p-Erk 1/2
Total Erk 1/2
Figure 7. CCL22 treatment induces phosphorylation of Akt. 
MJ cells were treated with CCL22 (100ng/mL) and cell lysates were
subject to immunoblotting with various mAbs (anti-human/mouse/
rat pan-Akt), affinity-purified rabbit anti-phospho-Akt (S473),
anti-human/mouse/rat pan-ERK1/ERK2, and anti-phospho-ERK1/
ERK2(T202/Y204) (R&D Systems) at 4°C overnight.
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Figure 6. CCL22 and CCL17 mildly enhance cell survival of MJ cells under nutrition deprivation. Cells were seeded in 96-well plates
with culture medium containing FBS at only 0.5%, and treated with CCL22, CCL17, or CXCL12 at 50 and 100 ng/mL concentrations
in triplicate. Cells treated with PBS only or culture medium containing 20% FBS were used as controls. Cell viability was measured
by colorimetric method with absorbance reading at 450 nm. *p < 0.05, versus non-chemokine control in low-serum conditions.
MJ cells. Moreover, Cronshaw et al showed that CCL22
could induce a more lasting Akt phosphorylation in
Th2 cells than CCL17 [34], which is also in line with our
results regarding MJ cell CCR4 signaling (Figure 7).
In skin milieu, CCL22 has been found to be mainly
expressed by DCs (both in the epidermis and dermis),
while CCL17 appears to be mostly produced by KCs
and ECs [26,35], but also by DCs [30]. Herein, we have
confirmed this specific pattern of chemokine expres-
sion in vitro (Figure 5C). Note that while CCL17 is
expressed by all three types of cells (KCs, ECs, and
DCs), CCL22 seems to be predominantly expressed
by DCs. More importantly, in the present study, we
further demonstrated that CM from DCs has a supe-
rior effect to enhance transendothelial migration of
MJ cells compared with KC-derived CM (Figure 5D),
suggesting a pivotal role for DCs in the migration of
CTCL cells toward the dermis through the vascular
barrier. Given that CCL22 is a more potent (than
CCL17) inducer of transendothelial migration of MJ
cells and given the wide distribution (in both epider-
mis and dermis) and high motility of DCs, it is likely
that DCs, rather than KCs or ECs, play a more deci-
sive role in mediating transendothelial migration of
MJ cells to skin dermis. Moreover, DCs may continue
to impose major effects on CTCL cells after their
migration into the dermis. It has also been found that
CCL22 and CCR4 are involved in the formation of 
T lymphocyte-DC clusters in human inflamed skin
[27]. Berger et al demonstrated that CTCL cells can 
be reproducibly grown in culture for 3 months when
cocultured with DCs [36], and further found that
CTCL cells adopt phenotypes of T-regulatory (Treg)
cells (expression of CD25/CTLA-4 and FoxP3) after
interaction with DCs [37]. The fact that CTCL cells are
primed (by DCs) into Treg-like cells may explain the
immunosuppressive nature of CTCL, in accordance
with a recent report from Curiel et al [33] demonstrat-
ing that immune-suppressing Treg cells in ovarian
cancer microenvironment have high CCR4 expres-
sion, and in vivo treatment with a mAb to CCL22 (but
not a mAb to CCL17) decreased migration of Treg
cells to tumors, thus further exemplifying the close
relations among CTCL, Treg cells, cancer immunity,
and the CCR4-CCL22 interaction. Collectively, these
findings, including ours, imply that soluble media-
tors secreted by DCs, especially CCL22, play critical
roles in many aspects of the skin homing process 
of CTCL cells, and also in subsequent survival and
remodeling of CTCL cells in skin. More importantly, in
line with the report from Curiel et al [33], our find-
ings may favor the selective targeting of CCL22, rather
than CCL17, in the development of novel therapeu-
tics against CCR4-mediated tumorigenesis, including
CTCL.
Integrin-mediated firm arrest of CTCL cells on
endothelial cells, activated by so-called “inside-out”
signaling downstream of chemokine receptors [38],
appears to also be important for CTCL skin homing.
However, it has not been clearly characterized which
integrins play a relatively more important role in the
transendothelial migration of CTCL cells. Nevertheless,
a previous report showed that the expression of
VCAM-1, the main ligand for α4 integrin, was upreg-
ulated in the dermal endothelium of CTCL lesions [39].
Herein, we have demonstrated that α4 integrin, but
not β2 integrin, enhances the adhesion of MJ cells on
VCAM-1 following CCR4 signaling in vitro (Figure 4).
More importantly, we have shown that transendothe-
lial migration of MJ cells, either enhanced by CCL22
or DC-derived CM, is dependent on α4 integrin
(CD49d), indicating that in certain pathologic condi-
tions like MF, certain sets of chemokine signaling
(CCR4/CCL22) and integrin type (α4) may have a
predominant role in controlling integrin-mediated
adhesion, as suggested by a previous report [40].
We cannot exclude that chemokines other than
CCL22 play some roles in the tumorigenesis of CTCL.
Indeed, a previous report noted that skin homing of
Sézary cells may involve CXCR4 signaling [41]. By
qPCR, we also found that the expression level of
CXCR4 in MJ cells is higher than that of CCR4; how-
ever, while CCR4 is differentially expressed by MJ and
control cells (Hut78 and mTC), the CXCR4 expres-
sion level (by qPCR) is similar between MJ cells and
other CTCL cell lines (HH and Hut78), but much
lower than that in CD4+CD45RO+ T cells (∼7-fold less),
indicating a more specific role of CCR4 in CTCL
pathogenesis. Given that CCL17 expression (produc-
tion) is widely distributed in skin (from KCs, DCs,
and ECs) it may still be able to contribute, to some
extent, to the skin homing and tumorigenesis of CTCL
(Figure 6). As suggested by Mariani et al [32], CCL17
may still play a role in promoting the arrest of rolling
CTCL cells on ECs; meanwhile, the expression of CCR4
in CTCL cells remains sensitive to CCL22 stimulation
and capable of mediating subsequent transendothelial
migration of CTCL toward the dermis.
CCR4 function in CTCL cell lines
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Using currently available CTCL cell lines, we have
demonstrated the differential expression of CCR4
between one MF-derived cell line and one SS-derived
cell line, and further shown the differential functional
capacities of CCL22 and CCL17 in mediating CCR4-
dependent adhesion and transendothelial migration
cascades of MJ cells. Given the long-existing barriers in
CTCL research caused by rare case number, difficulty
in isolating CTCL cells, and lack of a proper animal
model, these currently available CTCL cell lines may
serve as legitimate tools for studies involving CCR4-
mediated CTCL skin homing and tumorigenesis. More
importantly, as CCR4 has become one of the main
targets to develop novel therapies for cancer and
viral infection [42], the MJ cell line, with its higher
expression of CCR4 (versus Hut78 and mTC cells)
and greater sensitivity to CCL22 (versus CCL17), may
well serve as a decent model for studies involving
CCR4- or CCL22-targeting therapies.
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皮膚 T 細胞淋巴瘤屬於記憶型 T 淋巴球細胞所形成的腫瘤，主要影響的部位為人體
的皮膚。雖然皮膚 T 細胞淋巴瘤在臨床上有許多不同的分型，然而大部份的皮膚 T 細
胞淋巴瘤都有一共同之特色，就是移行至皮膚的能力。皮膚 T 細胞淋巴瘤移行的調控
機轉大部分仍不明朗；過往的研究雖然顯示特定的趨化激素受體 (chemokine 
receptor) 於皮膚 T 細胞淋巴瘤中有提高之表現，然而這些趨化激素受體是否真正可
以調控皮膚 T 細胞淋巴瘤移行仍屬未知。在本研究中，我們發現特定趨化激素受體 
CCR4 在不同種類的皮膚 T 細胞淋巴瘤細胞株中有不同之表現：來自蕈狀肉芽腫 
(mycosis fungoides，惡性 T 淋巴細胞絕大多數集中於皮膚 ) 的細胞株 (MJ) 相對於
來自 Sézary syndrome (部分惡性 T 淋巴細胞存在於週邊血液 ) 的細胞株 (Hut78) 
有較明顯的 CCR4 之表現。我們進一步進行一系列的 in vitro 功能測試 (趨化性，
integrin 活化與黏著，血管內皮穿透 )，我們發現具有較強 CCR4 表現之 MJ 細胞株
對於趨化激素 CCL22 (CCR4 之 ligand) 所引發之各種功能性表現都比對照組細胞株
要明顯。這些結果顯示趨化激素受體 CCR4 可能在皮膚 T 細胞淋巴瘤移行的調控機
轉中扮演重要角色。
關鍵詞：趨化激素受體 CCR4，趨化激素，皮膚 T 細胞淋巴瘤
(高雄醫誌 2008;24:577–90)
